uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says

uniQure (NASDAQ:QURE) had its target price raised by analysts at Mizuho from $7.00 to $20.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Mizuho’s target price indicates a potential upside of 17.79% from the company’s current price.

Several other analysts have also recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Royal Bank of Canada raised their price target on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Leerink Partners upped their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Stock Up 9.8 %

Shares of NASDAQ QURE opened at $16.98 on Thursday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50 day moving average is $8.13 and its two-hundred day moving average is $6.76. uniQure has a 52-week low of $3.73 and a 52-week high of $17.71. The firm has a market cap of $827.66 million, a price-to-earnings ratio of -3.42 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. Research analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently made changes to their positions in QURE. Vanguard Personalized Indexing Management LLC increased its position in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the period. Geode Capital Management LLC increased its holdings in shares of uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares during the period. American Century Companies Inc. raised its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the last quarter. Finally, RTW Investments LP acquired a new stake in uniQure during the 3rd quarter worth $49,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.